25,000 Shares in Alector, Inc. (NASDAQ:ALEC) Acquired by Apollon Wealth Management LLC

Apollon Wealth Management LLC bought a new stake in shares of Alector, Inc. (NASDAQ:ALEC) during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 25,000 shares of the company’s stock, valued at approximately $47,000.

A number of other large investors have also recently bought and sold shares of ALEC. SG Americas Securities LLC raised its holdings in shares of Alector by 27.9% in the fourth quarter. SG Americas Securities LLC now owns 39,334 shares of the company’s stock worth $74,000 after acquiring an additional 8,581 shares during the last quarter. Nordea Investment Management AB lifted its stake in shares of Alector by 5.1% during the fourth quarter. Nordea Investment Management AB now owns 165,713 shares of the company’s stock valued at $295,000 after buying an additional 7,971 shares during the period. JPMorgan Chase & Co. grew its stake in Alector by 64.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,728,823 shares of the company’s stock worth $12,716,000 after acquiring an additional 1,072,298 shares during the period. Barclays PLC grew its stake in Alector by 132.4% in the 3rd quarter. Barclays PLC now owns 176,800 shares of the company’s stock worth $824,000 after acquiring an additional 100,731 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Alector by 8.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,903,942 shares of the company’s stock worth $8,874,000 after purchasing an additional 148,357 shares during the period. Institutional investors and hedge funds own 85.83% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ALEC. Stifel Nicolaus downgraded Alector from a “buy” rating to a “hold” rating and set a $4.00 price objective for the company. in a research report on Monday, December 16th. Morgan Stanley cut shares of Alector from an “equal weight” rating to an “underweight” rating and decreased their target price for the stock from $10.00 to $3.00 in a research report on Tuesday, November 26th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Alector in a research report on Tuesday, November 26th. Mizuho lowered shares of Alector from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $9.00 to $2.50 in a research report on Tuesday, December 17th. Finally, HC Wainwright decreased their price target on shares of Alector from $35.00 to $7.00 and set a “buy” rating on the stock in a report on Friday, November 29th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Alector presently has an average rating of “Hold” and an average target price of $3.75.

Insider Activity

In other Alector news, CEO Arnon Rosenthal sold 52,172 shares of Alector stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $2.52, for a total transaction of $131,473.44. Following the sale, the chief executive officer now directly owns 2,507,074 shares in the company, valued at $6,317,826.48. The trade was a 2.04 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Sara Kenkare-Mitra sold 26,500 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $2.52, for a total value of $66,780.00. Following the transaction, the insider now owns 565,215 shares of the company’s stock, valued at approximately $1,424,341.80. This trade represents a 4.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 95,161 shares of company stock worth $239,806 over the last 90 days. Company insiders own 9.10% of the company’s stock.

Alector Trading Up 1.8 %

Shares of NASDAQ ALEC opened at $1.70 on Friday. The company has a market cap of $166.48 million, a P/E ratio of -1.00 and a beta of 0.61. Alector, Inc. has a 12-month low of $1.55 and a 12-month high of $7.58. The stock has a fifty day moving average price of $1.82 and a 200 day moving average price of $3.74.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.